Entity family

Browse diseases

Named diseases, disorders, syndromes, injuries, and health conditions. Examples include epilepsy, diabetes, stroke.

23,712articles mentioning diseases

125,551disease mentions

18,081distinct diseases extracted

0%of mentions human-reviewed

Filter articles

JournalContent resourceEvidence policyAutomated confidence floorArticles per pageReset filters

“Reviewed + threshold” includes every confirmed correction plus unreviewed proposals at or above the selected model score.

All extracted diseases

Showing 10,621–10,680 of 18,081, ordered by supporting articles. Choose a disease to see its evidence.

Neonatal orbital cellulitis1 Neonatal osteomyelitis1 Neonatal respiratory system immaturity1 Neoplasm or Neoplasms1 Nephrogenic diabetes insipidus1 Nephropathy34391 Neurocutaneous melanocytosis1 Neurodegeneration-Multiple Diseases1 Neurodegenerative pathologies1 Neurodevelopmental delay1 Neurodevelopmental disabilities (NDs)1 Neuroendocrine carcinomas1 Neuroendocrine lung tumours1 Neurofascin 155 autoimmune nodopathy1 Neurofibromatosis type 1-associated diffuse lung disease1 Neurogenic bowel dysfunction (NBD)1 Neurological diagnoses1 Neuromuscular diseases (NMD)1 Neuromyelitis optica spectrum disorder (NMOSD)1 Neuromyelitis optica spectrum disorders (NMOSD)1 Neuronal Ceroid Lipofuscinosis Type 21 Neuronal intranuclear inclusion disease1 Neuropathic incisional pain1 Neuropathies1 Neuropathy41461 Neuropathy49201 Neurotoxic myelitis1 Nevus lipomatosus cutaneous superficialis1 New York Heart Association class III or IV heart failure1 Niemann-Pick C1 Niemann-Pick type C1 Nikolsky breast cancer1 Nipah virus1 Nocardia cyriacigeorgica1 Nocardia keratitis1 Node-first Kawasaki disease1 Noise-induced hearing loss (NIHL)1 Non alcoholic fatty liver disease (NAFLD)1 Non- Hodgkin's Lymphoma1 Non-24-hour sleep–wake rhythm disorder1 Non-Hodgkin lymphoma101 Non-ST-segment-elevation myocardial infarction1 Non-acute subdural hematoma1 Non-acute subdural hematomas1 Non-ampullary duodenal adenomas1 Non-aneurysmal subarachnoid haemorrhage1 Non-battle injury1 Non-compressible torso hemorrhage (NCTH)1 Non-dilated left ventricular cardiomyopathy (NDLVC)1 Non-dystrophic myotonia1 Non-fatal TBI1 Non-functioning pancreatic neuroendocrine tumours1 Non-gestational choriocarcinomas1 Non-insertional Achilles tendinopathy1 Non-ischemic cerebral enhancing (NICE) lesions1 Non-pancreatic periampullary carcinomas1 Non-pedunculated colonic neoplasia (NPCN)1 Non-segmental vitiligo1 Non-specific low back pain (NSLBP)1 Non-specific neck pain1

View all 18,081 diseases on one page

Articles mentioning diseases

23,712 articles · page 260 of 1976

PO:09:234 Neuropsychiatric involvement in patients with systemic lupus erythematosus

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

93.5%

NPSLE SLE Neuropsychiatric SLE epilepsy

…(CNS) and peripheral nervous system (PNS)—based on the 1999 ACR NPSLE case definitions and current literature. Statistical analyses w…

PO:10:257 Addition of a calcineurin inhibitor (CNI) to glucocorticoids (GC) and mycophenolate mofetil (MMF) increased the frequency of renal response in lupus nephritis (LN) due to a reduction in proteinuria

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

97.5%

lupus nephritis SLE systemic lupus erythematosus Anifrolumab hydroxychloroquine tacrolimus

…vel at 12 hours of 4-6 ug/L.Results Before TAC, the duration of lupus nephritis (LN) was 46 (in the range of 12-162) months. The drug therapy p…

PO:10:271 From patient voice to clinical practice: recommendations from the national evaluation of the lupus service in NHS wales

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

99.8%

lupus Rheumatology biologic treatments Welsh Government CEDAR NHS British Society for Rheumatology

…ental health support, inter-speciality fragmented care, and low lupus awareness among non-specialists. The findings provided a clear …

PO:11:274 RESET SLE: clinical trial evaluating rese-cel (resecabtagene autoleucel), a fully human, autologous 4–1BB anti-CD19 CAR T cell therapy in non-renal SLE and lupus nephritis (LN)

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

99.7%

SLE Rese-cel NCT06121297

… allowing patients to achieve meaningful clinical responses off SLE therapies. Both cohorts are fully enrolled, with additional pos…

PT1:08 A cross-reactive response to symmetrical dimethylarginine defines anti-Sm autoantibodies in systemic lupus erythematosus

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

96.8%

Systemic lupus erythematosus SLE SLE-specific

…Objectives Systemic lupus erythematosus (SLE) is a chronic autoimmune disease causing multi-organ damag…

PT2:02 Plasma metabolomic profiling reveals serine-centered immunometabolic modulation by SGLT2 inhibition in lupus nephritis

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

98.1%

lupus nephritis SLE systemic lupus erythematosus dapagliflozin dapagliflozin-associated Dapagliflozin-treated

…y provides novel insights into systemic metabolic remodeling in lupus nephritis and identifies dapagliflozin-associated shifts in amino acid an…

PT3:03 Rapid Oral glucocorticoid discontinuation or dose reduction among US patients with SLE receiving belimumab in a real-world setting

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

95.9%

SLE lupus LN Belimumab prednisone-equivalent BEL GSK OGC

…roportion of moderate (74.3% vs 66.9%) or severe (3.7% vs 2.2%) SLE, but similar baseline organ damage ( table 1). Baseline moderat…

PT3:04 Correlation between clinical remission and steroid withdrawal in systemic lupus erythematosus: a retrospective analysis of a monocentric cohort characterized by intensive immunosuppressant use

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

99.3%

SLE diabetes mellitus osteoporosis with fracture cataract arterial hypertension cardiovascular events Rituximab hydroxychloroquine Belimumab Anifrolumab

…ing that steroid-free remission is a realistic clinical goal in SLE management. Steroid-free management of more inflammatory manife…

PT4:05 Tofacitinib versus belimumab in maintenance therapy of systemic lupus erythematosus: a real-world CSTAR cohort study

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

95.4%

SLE Systemic lupus erythematosus Lupus Erythematosus Belimumab Tofacitinib TOF BEL

…d, multicenter, retrospective cohort study based on the Chinese SLE Treatment and Research Registry (CSTAR). Maintenance therapy wa…

PT6:03 Autoantibody signatures predict atherosclerosis progression and statin response in juvenile-onset systemic lupus erythematosus

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

87.6%

JSLE JSLE-specific Cardiovascular disease CVD-risk atorvastatin atorvastatin-arm statin

…ersus placebo (1:1) across 21 North American sites. Ninety-four JSLE patients (mean [SD] age 15.3 [2.4] years; 78% female) with matc…

PT7:06 Bridging physician-defined targets and patient-perceived health: associations with PASS in the large multicenter systemic lupus erythematosus cohort RELESSER

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

94.8%

systemic lupus erythematosus SLE fibromyalgia SLEDAI-2K DORIS-R

…o identify clinical and socio-demographic correlates of PASS in systemic lupus erythematosus (SLE).Methods We analyzed data from the large multicenter RELES…

S15:02 Dapirolizumab pegol and flare reduction in patients with SLE in a 48-week phase 3 trial: an updated post hoc analysis of alternative definitions of flares that reflect clinical practice

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

88.0%

BILAG-2004 dapirolizumab pegol DZP

… of patients receiving PBO+SOC had moderate and moderate/severe BILAG-2004 flares using the alternative definitions; lower proportions of …